Steven Boyd’s Armistice Capital filed his first activist campaign this month, with a 5.4% stake in Spectrum Pharmaceuticals. Boyd worked at Senator Investment Group, York Capital and SAB Capital before starting Armistice in 2012. He’s done well on the passive side, waging a number of 13G campaigns, but this is the first time he’s trying his hand as an activist.
Recall that we noted the fund sent a letter to CEO and Chairman Dr. Rajesh Shrotriya in mid-May.
Armistice has laid out a host of grievances against the company’s board and executives, most notably in terms of compensation. As the stock has dropped by nearly 50% over the past three years, Dr. Shrotriya has earned over $20 million (5% of the market cap) in compensation.
On the night that a court ruled against SPPI in a case that opened up its most prominent drug, Fusilev, to generic competition, the company filed an 8-K announcing $2 million in bonuses and increases in base salaries for its top four executives.
The backup plan, a company-wide buyout. But Working against us:
Top 5 drugs making up nearly 90% of sales are already showing declines
Any big move to the upside triggers options and convertibles exercise of these options and convertible bonds, diluting the share count by up to a third.
Sign up for Activist Strategy to read the rest - AS is the all in one using activist targeted stocks for idea generation